Merck and Moderna Launch Phase III Study for Individualized Neoantigen Therapy in Lung Cancer
US pharmaceutical companies Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) and Moderna Inc. (NASDAQ:...
NASDAQ: MRNA
Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment
Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies
Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...
Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan
Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...
Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide
Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...
Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai
S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...
CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA...
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...
Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants
Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...
Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development
Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week...
Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina
Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III...
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology
US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district...
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...
Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...